Abstract

Imaging of sigma receptors in the living human brain is of interest because these receptors are potent targets for the treatment of neurological and neuropsychiatric diseases and brain ischemia. A number of radioligands have been developed for the imaging of sigma receptors, and a few, including [11C]SA4503, have been used in clinical studies for imaging in the human brain. The sigma1 receptor is distributed throughout the human brain. A widespread decrease in [11C]SA4503 binding in patients with Alzheimer's disease and a significant decrease in binding on the more affected side of the anterior putamen in patients with Parkinson's disease have been found. Drug-loading [11C]SA4503-positron emission tomography studies using therapeutic drugs for neurological and neuropsychiatric disorders have shown that some of the drugs had an affinity for sigma1 receptors in the human brain in addition to their main targets.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call